MedTrace Logo

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

NCT06937866 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-11-21

No results posted yet for this study

Summary

This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed, refractory metastatic GCT.

Conditions

  • Germ Cell Tumor

Interventions

DRUG

Zanzalintinib

Two zanzalintinib doses of 40mg and 60mg. The initial starting dose of zanzalintinib will be 40mg. The patients will receive zanzalintinib orally daily continuously for 28 day cycles.

DRUG

Etoposide Capsule

Oral daily for 21 days of each 28 day cycle.

Sponsors & Collaborators

  • Exelixis

    collaborator INDUSTRY

  • Indiana University

    lead OTHER

Principal Investigators

  • Jennifer King, MD · Indiana University Simon Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-12
Primary Completion
2030-03-31
Completion
2031-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06937866 on ClinicalTrials.gov